Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
On the other hand it
2024-05-21
On the other hand, it is important to note that FR is different from the regulation of daily/circadian rhythms [44]. Based on models of physical systems [45], [46], it has been hypothesized that fractal physiological fluctuations reflect a network of elaborate regulatory processes interacting across
-
A large number of aldose reductase
2024-05-21
A large number of aldose reductase inhibitors have been prepared synthetically, and a limited number of them are therapeutically used. However, none of them is satisfactory. Here, Cannabis extracts with high content of non-psychotropic phytocannabinoids CBD/CBDA or CBG/CBGA showed statistically sign
-
br Conclusion Biotransformation of trachyloban oic acid by
2024-05-20
Conclusion Biotransformation of trachyloban-19-oic KU-55933 mg by S. racemosum provided three products. Oxidation of compound 1 at C-17 (2–3), as well as rearrangement of 1 into a kaurane diterpene hydroxylated in C-16 and C-17 (4) were crucial for increasing AChE inhibitory activity. Compound 3
-
Acknowledgements The work was supported by grants from
2024-05-20
Acknowledgements The work was supported by grants from Swedish Research Council (J.Z.H.) (A.R.M.). We thank Protein Science Facility (PSF), Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden. We thank Prof. Ralf Morgenstern (Department for Environmental Medic
-
VEGFR Tyrosine Kinase Inhibitor II mg Drug resistance develo
2024-05-20
Drug resistance development often involves structurally un-related drugs and, specifically both conventional and targeted agents. IGROV-1/Pt1 VEGFR Tyrosine Kinase Inhibitor II mg are characterized by resistance to cisplatin and reduced sensitivity to inhibitors of EGF-R and MEK, the up-stream acti
-
Many reports have well documented that signaling pathways pl
2024-05-20
Many reports have well documented that signaling pathways play a pivotal role in controlling longevity. The most studied of these pathways is the IGF-1 pathway [11,12]. A disruption of this pathway has been found to extend longevity in different groups of species starting from Caenorhabditis elegans
-
br Colorectal carcinoma The growth rate of murine
2024-05-20
Colorectal carcinoma The growth rate of murine colon adenocarcinoma tumors decreased upon inhibition of 5-LOX, an enzyme that harbors counteracting properties to 15-LOX [28]. It is not clear whether 15-LOX was associated with this phenomenon, but its expression is induced in the colon carcinoma c
-
Hypoxia induced replication arrest has
2024-05-20
Hypoxia-induced replication arrest has been demonstrated in a variety of organisms in addition to mammals; including Zebrafish , , and (brine shrimp) which have been shown to survive for 4 years and longer in anoxic conditions . Despite this breadth of study, little is known about the mechanism of h
-
Gefitinib br Introduction Increasing number of mycosis
2024-05-20
Introduction Increasing number of mycosis infections has been reported during the past several years because of the rise in the number of immuno-compromised individuals in subtropical and tropical countries with high mortality and morbidity [1], [2]. Trichophyton mentagrophytes, Trichophyton rubr
-
54011 synthesis Kuda et al reported that the activity of
2024-05-20
Kuda et al. (1997) reported that the activity of aminopeptidase A (ApA) but not aminopeptidase B (ApB) nor aminopeptidase N (ApN) was decreased in plasma from patients with Alzheimer's disease (AD). More recently Puertas et al. (2013) reported that the activities of plasma ApA, ApB, ApN and IRAP wer
-
br Concluding remarks The past decade has seen rapid advance
2024-05-20
Concluding remarks The past decade has seen rapid advances in our understanding of the metabolic reprogramming that occurs during tumorigenesis. Strategies to target specific nodes of cancer cell amino luciferase firefly metabolism have progressed from preclinical studies to clinical trials, and
-
Some of the earliest LOX inhibitors were redox
2024-05-20
Some of the earliest 12-LOX inhibitors were redox inhibitors, including nordihydroguaiaretic MCC950 sodium (NDGA), BW 755C, and baicalein 48, 49, 50. Redox inhibitors block the oxidation of the nonheme iron at the cataylytic site, preventing its conversion from the inactive (Fe2+) to the active (Fe
-
Aldose reductase AR is an NADPH dependent aldo keto reductas
2024-05-18
Aldose reductase (AR), is an NADPH-dependent aldo-keto reductase very well studied as a catalyst of glucose conversion to sorbitol in the polyol pathway [11], [12]. In the diabetic lens characterized by chronically high levels of glucose, AR is responsible for production of high levels of sorbitol a
-
Two cell surface trans membrane receptors have
2024-05-18
Two cell-surface trans-membrane receptors have been identified for adiponectin, AdipoR1 and AdipoR2 [21], and adiponectin action is known to signal through these receptors and the docking protein APPL1 [22]. In muscle and liver cells, signal transduction involves the phosphorylation and activation o
-
br Materials and methods br Results br Discussion
2024-05-18
Materials and methods Results Discussion This study demonstrates that treatment with a selective adenosine kinase inhibitor ABT-702, thereby enhancing extracellular adenosine, can provide partial protection from age-related hearing loss in C57BL/6J mice. Chronic treatment with ABT-702, comm
16070 records 138/1072 page Previous Next First page 上5页 136137138139140 下5页 Last page